Phase 3 randomized study of daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) vs VTd in transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 1 results.

Philippe Moreau,Michel Attal,Cyrille Hulin,Marie-Christine Béné,Annemiek Broijl,Denis Caillot,Michel Delforge,Thomas Dejoie,Thierry Facon,Jérôme Lambert,Xavier Leleu,Margaret Macro,Aurore Perrot,Sonja Zweegman,Tahamtan Ahmadi,Christopher Chiu,Lixia Pei,Jessica Vermeulen,Hervé Avet-Loiseau,Pieter Sonneveld,Hovon

Phase 3 randomized study of daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) vs VTd in transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 1 results.

2019

8003Background: VTd is a standard of care (SoC) for TE NDMM. CD38 mAb DARA significantly reduced the risk of progression/death and improved CR and MRD-negative rates in relapsed refractory MM or tr...

Keywords:

Refractory
Pathology
Bortezomib/thalidomide
Dexamethasone
Randomized controlled trial
Dara
Daratumumab
Oncology
Internal medicine
Multiple myeloma
Medicine
newly diagnosed
standard of care

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations